Fennec Pharmaceuticals Inc (FENC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.62 (-1.48%), Market cap $0.33B, 52-week low–high $5.77 ~ $9.88.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was for
Financial statements, price targets, institutional (13F) holdings and related news for Fennec Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Fennec Pharmaceuticals Inc trades at $10.62 (-1.48%). Real-time quotes and charts are available on BlackAll Trade.
Fennec Pharmaceuticals Inc has a market cap of about $0.33B.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the